ARTICLE | Clinical News
SB061: Phase I/II started
July 11, 2016 7:00 AM UTC
Symic and Nordic Bioscience began the double-blind, placebo-controlled, Estonian Phase I/II MODIFY-OA trial to evaluate intra-articular injections of SB061 in about 90 patients. In 2015, Symic and Nor...